Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Esophageal Cancer Clinical Trials

A listing of Esophageal Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (16) clinical trials

A clinical research study for the treatment of Esophageal Cancer

The investigators propose to treat patients with metastatic esophageal cancers and dysphagia with two fractions of brachytherapy followed by pembrolizumab. The brachytherapy is hypofractionated and will provide a radiation dose of sufficient intensity to induce the release of tumor-derived antigens and trigger an antitumor immune response. The simplicity of the ...


A clinical research study of S-1 de-escalation, Chemotherapy by Investigator's choice for the treatment of Esophageal Adenocarcinoma, Gastric Cancer, Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer, Gastric Adenocarcinoma

Open-label, multi-center, controlled, randomized, parallel-group phase II trial in patients with metastatic esophagogastric cancer having received induction chemotherapy. Patients will be registered before or after application of a three-months induction chemotherapy . This 12-week induction therapy will consist of one of the following regimens: FLO/mod. Folfox-6, Cisplatin/5-FU, Cisplatin/S-1, FLOT, EOX/EOF ...


A clinical trial seeking patients for a research study for the treatment of Cellular aspects of, Cytology, gastrointestinal endoscopy, Gastric Cancer, Cytological Techniques, Esophageal Cancer, Esophagogastroduodenoscopy

Esophageal cancer is a common malignancy with a very poor prognosis. The principal reason for its poor prognosis is that most tumors are asymptomatic and go undetected until they have spread beyond the esophageal wall and are unresectable. Significant reduction in esophageal cancer mortality will require successful strategies to diagnose ...

Phase N/A

A clinical trial seeking patients for a research study for the treatment of Esophageal Cancer

Study Treatment: If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups: If you are in Group 1, you will receive IMRT. If you are in Group 2, you ...


A clinical trial sponsored by The Netherlands Cancer Institute for a research study for the treatment of Chemoradiation, Esophageal Cancer

A single center prospective observational study will be performed in esophageal cancer patients. This study registers motion of the esophageal tumor, using 4D planning CT scans and repeated 4D CBCT scanning. Motion of fiducial markers inserted into the esophageal wall, will be used as a surrogate for tumor motion in ...

Phase N/A

A clinical trial to evaluate treatments for patients with Lung Neoplasm, Malignant Pleural Mesotheliomas NOS, Esophageal Cancer, Bronchial Neoplasm, Mediastinal or Chest Wall Neoplasms, Pulmonary Metastases From Cancers

Background -Lung and esophageal cancers as well as malignant pleural mesotheliomas exhibit profound alterations in chromatin structure, which may impact the clinical course of these neoplasms. -To date, epigenetic alterations in primary thoracic malignancies and neoplasms metastatic to the chest have not been evaluated in a systematic manner. Objectives To ...

Phase N/A

A Phase 3 clinical study for patients using 5-FU, Placebo, Cisplatin

The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) chemotherapy versus placebo plus cisplatin and 5-FU chemotherapy as first-line treatment in participants with locally advanced or metastatic esophageal carcinoma. The primary efficacy hypotheses are that both progression-free survival (PFS), according to ...


Patients are needed to participate in a clinical research study to evaluate Recurrent Glioma, Thyroid Adenoma, Colorectal Cancer, Lung Neoplasm, Uterine Corpus Cancer, Ovarian Cancer, Recurrent Thyroid Gland Carcinoma, Recurrent Breast Carcinoma, Recurrent Colon Carcinoma, Recurrent Liver Carcinoma, Pancreatic Cancer, Malignant neoplasm of kidney, Ductal Carcinoma In Situ, Recurrent Pancreatic Carcinoma, melanoma, Malignant neoplasm of prostate, bladder cancer, Advanced Malignant Solid Neoplasm, Recurrent Lymphoma, Renal Cell Carcinoma, Uterine Cancer, Endometrial Carcinoma, Malignant neoplasm of colon, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Refractory Lymphoma, Lymphoma, Breast Cancer, Cervical Cancer, Skin Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Head and Neck Carcinoma, Esophageal Carcinoma, Refractory Plasma Cell Myeloma, Recurrent Cervical Carcinoma, Multiple Myeloma, Recurrent Lung Carcinoma, Head and Neck Carcinoma, Recurrent Skin Carcinoma, Recurrent Bladder Carcinoma, Recurrent Malignant Solid Neoplasm, Rectal Cancer, Recurrent Plasma Cell Myeloma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Glioma, Recurrent Rectal Carcinoma, Cervical Intraepithelial Neoplasia, Liver and Intrahepatic Bile Duct Carcinoma, Gastric Carcinoma, Recurrent Colorectal Carcinoma, skin cancer, Refractory Malignant Solid Neoplasm

PRIMARY OBJECTIVES: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced ...


A clinical research study of Ropidoxuridine

PRIMARY OBJECTIVES: I. To conduct a phase I dose escalation trial, to determine the safety and the maximum tolerated dose (MTD), of oral (po) IPdR (ropidoxuridine) given daily for 28 consecutive days with concurrent intensity-modulated radiation therapy (IMRT) in patients with advanced gastrointestinal cancers treated with palliative radiation. SECONDARY OBJECTIVES: ...


A clinical trial sponsored by National Cancer Institute (NCI) for a research study for the treatment of Mesothelioma, Thymoma, Germ cell tumor, Esophageal Cancer, Lung Neoplasm

Background Increasing evidence indicates that activation of stem cell gene expression is a common mechanism by which environmental carcinogens mediate initiation and progression of thoracic malignancies. Similar mechanisms appear to contribute to extra-thoracic malignancies that metastasize to the chest. Utilization of pharmacologic agents, which target gene regulatory networks mediating stemness ...